Genome & Company (KOSDAQ:314130)

Genome & Company Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 15, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	276,151	85,207	176,209	245,897	468,827	1,048,465
Market Cap Growth	207.86%	-51.64%	-28.34%	-47.55%	-55.28%	224.28%
Enterprise Value	265,279	89,070	151,242	185,907	383,841	-
Last Close Price	7970.00	2750.00	6245.00	8725.00	17350.00	39750.00
PS Ratio	10.64	3.07	12.33	17.46	1038.96	6962.78
PB Ratio	2.90	0.86	1.55	1.63	4.13	9.11
P/TBV Ratio	4.55	3.40	4.83	3.73	8.10	9.84
EV/Sales Ratio	10.22	3.21	10.58	13.20	850.63	-
Debt / Equity Ratio	0.29	0.32	0.23	0.04	0.06	0.02
Asset Turnover	0.18	0.18	0.09	0.09	0.00	0.00
Inventory Turnover	1.99	2.59	3.53	4.76	-	-
Quick Ratio	1.69	2.80	3.09	9.83	8.03	36.89
Current Ratio	1.93	3.08	3.36	10.49	8.32	37.00
Return on Equity (ROE)	-34.26%	-25.26%	-38.36%	-43.15%	-31.51%	-80.88%
Return on Assets (ROA)	-11.92%	-9.78%	-20.55%	-23.17%	-17.48%	-21.33%
Return on Invested Capital (ROIC)	-13.45%	-11.16%	-23.20%	-25.95%	-19.03%	-38.58%
Return on Capital Employed (ROCE)	-26.60%	-20.60%	-41.40%	-35.50%	-28.30%	-22.60%
Earnings Yield	-10.07%	-23.60%	-26.94%	-21.08%	-7.28%	-2.93%
FCF Yield	-7.10%	-23.82%	-28.99%	-20.50%	-6.19%	-1.88%
Buyback Yield / Dilution	-93.35%	-7.88%	-0.32%	-4.71%	-39.60%	-20.11%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.